Skip to content

Quick ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.1×0.0×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
3.2×-2.4×
Viking Therapeutics logo
Viking TherapeuticsVKTX
5.7×-38.5×
Theravance Biopharma logo
Theravance BiopharmaTBPH
13.1×+8.4×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
2.5×+0.4×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.9×+2.3×

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s quick ratio?
Gyre Therapeutics, Inc. (GYRE) reported quick ratio of 4.1× in Q1 2026.
How has Gyre Therapeutics, Inc.'s quick ratio changed year-over-year?
Gyre Therapeutics, Inc.'s quick ratio increased by 27.4% year-over-year, from 3.2× to 4.1×.
What is the long-term trend for Gyre Therapeutics, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s quick ratio has grown at a 0.0% compound annual growth rate (CAGR), from 5× to 5×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.